Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista® in Wet Age-Related Macular Degeneration
NEW YORK--(BUSINESS WIRE)--Ophthotech Corporation today announced that the primary endpoint was not achieved in its two pivotal Phase 3 clinical trials investigating Fovista® (pegpleranib).